Press release: Uppsala,
In parallel with animal studies, several activities are underway within Dicot's work to develop a potency drug with better properties than those of existing drugs. The next major milestone is human clinical trials planned to be launched during 2022.
Prior to these studies, the company needs to decide how the active substance of the drug candidate LIB-01 is to be supplied to the body, i.e., in which formulation. Dicot intends to develop a formulation that is administered subcutaneously and an oral one to evaluate which is best suited for the clinical trials.
To work with the formulation, Dicot has signed an agreement with two leading companies in the field. One in the US and one in
"An important part of the industrialization phase that Dicot initiated this year is to acquire solid and relevant expertise. It is therefore very satisfying that we now have strong partnerships with two of the world's most experienced companies in something as important as formulation", Dicot's CEO Göran Beijer comments.
For further information, please contact:
Göran Beijer, CEO
Tel: +46 (0) 706 63 60 09
E-mail: goran.beijer@dicot.se
About
Dicot is developing the drug candidate LIB-01 (formerly Libiguin), which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
https://news.cision.com/dicot-ab--publ-/r/dicot-signs-development-agreements-with-leading-suppliers-in-formulation,c3362863
https://mb.cision.com/Main/17172/3362863/1429042.pdf
(c) 2021 Cision. All rights reserved., source